| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
TSG101 Blocking Peptide for STJ503421 is synthetically produced from the 330-390 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
TSG101 |
| Gene ID: |
7251 |
| Uniprot ID: |
TS101_HUMAN |
| Immunogen Region: |
330-390 |
| Specificity: |
This blocking peptide is recommended for use in combination with TSG101 antibody, STJ503421 |
| Immunogen: |
Synthetic peptide taken within amino acid region 330-390 on Tumor susceptibility gene 101 protein. |
| Tissue Specificity | Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas. |
| Post Translational Modifications | Monoubiquitinated at multiple sites by LRSAM1 and by MGRN1. Ubiquitination inactivates it, possibly by regulating its shuttling between an active membrane-bound protein and an inactive soluble form. Ubiquitination by MGRN1 requires the presence of UBE2D1. |
| Function | Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis.the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-ST-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan. It may also play a role in the extracellular release of microvesicles that differ from the exosomes. |
| Peptide Name | Tumor Susceptibility Gene 101 ProteinEscrt-I Complex Subunit Tsg101 |
| Database Links | Reactome: R-HSA-162588Reactome: R-HSA-174490Reactome: R-HSA-917729Reactome: R-HSA-9610379Reactome: R-HSA-9615710 |
| Cellular Localisation | CytoplasmEarly Endosome MembranePeripheral Membrane ProteinCytoplasmic SideLate Endosome MembraneCytoskeletonMicrotubule Organizing CenterCentrosomeMidbodyMidbody RingNucleusMainly CytoplasmicMembrane-Associated When Active And Soluble When InactiveNuclear Localization Is Cell Cycle-DependentInteraction With Cep55 Is Required For Localization To The Midbody During Cytokinesis |
| Alternative Peptide Names | Tumor Susceptibility Gene 101 Protein proteinEscrt-I Complex Subunit Tsg101 proteinTSG101 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
